

## Republic of the Philippines Department of Health OFFICE OF THE SECRETARY

## GUIDELINES ON THE APPLICATION OF PHILIPPINE SOCIAL VALUES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) FOR PUBLIC CONSULTATION FROM 21 SEPTEMBER TO 05 OCTOBER 2022

The Republic Act (RA) No. 11223 also known as the Universal Health Care (UHC) Law mandates that all health technologies being considered for coverage or funding allocation from the Department of Health (DOH) and PhilHealth shall be recommended by the Health Technology Assessment Council (HTAC). It emphasizes the principles of universality of access, fairness, equity and the empowerment of the general population in the decision-making for the allocation and distribution of HTs to ensure healthcare access to all.

In its assessments and recommendations, the HTAC considers the ethical, legal, social and health systems impact (ELSHI) of HTs to reflect beliefs and preferences of Filipinos on health care. The goal of HTAC is to make the HTA process more responsive to Philippine social values that will inform health care coverage or funding decisions that are fair and relevant to the Philippine context.

In this regard, the HTAC, supported by the DOH HTA Division (HTAD), developed the *Guidelines* on the Application of Philippine Social Values on HTA. The draft interim guidelines on this are hereby presented to all stakeholders, for review and comments until 05 October 2022. Please see the editable copy of the guidelines attached to this advisory.

Should you have comments and/or additional inputs with the draft guidelines, you may coordinate with HTAD through email at <a href="http://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://https://htt

ANNA MELISSA S. GUERRERO, MD, MPH (HTA)

Director IV

Health Technology Assessment Division

Health Regulation Team